A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy

NCT07305974 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

IgA Nephropathy (IgAN)

Interventions

DRUG: RG002C0106
DRUG: placebo subcutaneous administration

Sponsor

Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.